Search

Your search keyword '"Esteban Villarrubia, Jorge"' showing total 21 results
Start Over Author "Esteban Villarrubia, Jorge"
21 results on '"Esteban Villarrubia, Jorge"'

1. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Author

Melero, Ignacio, de Miguel Luken, Maria, de Velasco, Guillermo, Garralda, Elena, Martín-Liberal, Juan, Joerger, Markus, Alonso, Guzman, Goebeler, Maria-Elisabeth, Schuler, Martin, König, David, Dummer, Reinhard, Reig, Maria, Rodriguez Ruiz, Maria-Esperanza, Calvo, Emiliano, Esteban-Villarrubia, Jorge, Oberoi, Arjun, Sabat, Paula, Soto-Castillo, Juan José, Koster, Kira-Lee, Saavedra, Omar, Sayehli, Cyrus, Gromke, Tanja, Läubli, Heinz, Ramelyte, Egle, Fortuny, Marta, Landa-Magdalena, Ana, Moreno, Irene, Torres-Jiménez, Javier, Hernando-Calvo, Alberto, Hess, Dagmar, Racca, Fabricio, Richly, Heike, Schmitt, Andreas M., Eggenschwiler, Corinne, Sanduzzi-Zamparelli, Marco, Vilalta-Lacarra, Anna, Trojan, Jörg, Koch, Christine, Galle, Peter R., Foerster, Friedrich, Trajanoski, Zlatko, Hackl, Hubert, Gogolla, Falk, Koll, Florestan J., Wild, Peter, Chun, Felix Kyoung Hwan, Reis, Henning, Lloyd, Peter, Machacek, Matthias, Gajewski, Thomas F., Fridman, Wolf H., Eggermont, Alexander M. M., Bargou, Ralf, Schöniger, Sandra, Rüschoff, Josef, Tereshchenko, Anastasiia, Zink, Carina, da Silva, Antonio, Lichtenegger, Felix S., Akdemir, Julia, Rüdiger, Manfred, L’Huillier, Phil, Dutta, Aradhana, Haake, Markus, Auckenthaler, Alexandra, Gjorgjioska, Ana, Rössler, Bernhard, Hermann, Frank, Liebig, Mara, Reichhardt, Daniela, Schuberth-Wagner, Christine, Wischhusen, Jörg, Fettes, Petra, Auer, Marlene, Klar, Kathrin, and Leo, Eugen

Published
2024
Full Text
View/download PDF

5. Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer.

Author

Esteban-Villarrubia, Jorge, Ballesteros, Pablo Alvarez, Martín-Serrano, Miguel, Vico, María Ruiz, Funes, Juan M, de Velasco, Guillermo, Castro, Elena, Olmos, David, Castellano, Daniel, and González-Billalabeitia, Enrique

Subjects
*TUMOR suppressor genes, *PTEN protein, *IMMUNE checkpoint proteins, *IMMUNOREGULATION, *PROSTATE cancer
Abstract

PTEN (phosphatase and tensin homolog) is a frequently lost tumor suppressor gene in prostate cancer, leading to aggressive tumor behavior and poor clinical outcomes. PTEN loss results in aberrant activation of the PI3K/AKT/mTOR pathway, promoting oncogenesis. These alterations also lead to an immunosuppressive tumor microenvironment with altered immune cell infiltration, cytokine profiles, and immune checkpoint regulation. This review aims to provide a comprehensive overview of the mechanisms underlying PTEN loss in prostate cancer and the consequent immune alterations observed in this subtype, thus underscoring the importance of understanding PTEN-mediated immune modulation for the development of effective therapeutic interventions in prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Author

Torres-Jiménez, Javier, Espinar, Javier Baena, de Cabo, Helena Bote, Berjaga, María Zurera, Esteban-Villarrubia, Jorge, Fraile, Jon Zugazagoitia, and Paz-Ares, Luis

Subjects
COMBINATION drug therapy, GENOMICS, CELLULAR signal transduction, IMMUNE checkpoint inhibitors, ONCOGENES, GENETIC mutation, LUNG cancer, DRUG resistance
Abstract

Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS). KRAS mutant NSCLC is a heterogenous group of diseases, different from other oncogene-driven tumors in terms of biology and response to therapies. Despite efforts to develop drugs aimed at inhibiting KRAS or its signaling pathways, KRAS had remained undruggable for decades. The discovery of a small pocket in the binding switch II region of KRASG12C has revolutionized the treatment of KRASG12C-mutated NSCLC patients. Sotorasib and adagrasib, direct KRASG12C inhibitors, have been approved by the US Food and Drug Administration (FDA) and other regulatory agencies for patients with previously treated KRASG12C-mutated NSCLC, and these advances have become practice changing. However, first-line treatment in KRASG12C-mutated NSCLC does not differ from NSCLC without actionable driver genomic alterations. Treatment with KRASG12C inhibitors is not curative and patients develop progressive disease, so understanding associated mechanisms of drug resistance is key. New KRASG12C inhibitors and several combination therapy strategies, including with immune checkpoint inhibitors, are being studied in clinical trials. The aim of this review is to explore the clinical impact of KRAS, and outline different treatment approaches, focusing on the novel treatment of KRASG12C-mutated NSCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.

Author

Esteban Villarrubia, Jorge, Alonso Gordoa, Teresa, Mellado-González, Begoña, Duran, Ignacio, Pinto, Alvaro, Sanchez, Alfredo, Font Pous, Albert, Vazquez-Estevez, Sergio, Puente, Javier, Grande, Enrique, Climent, Miguel Ángel, Maroto-Rey, Pablo, Perez-Gracia, Jose Luis, Ponce Aix, Santiago, Castellano, Daniel, and Gonzalez-Billalabeitia, Enrique

Published
2024
Full Text
View/download PDF

10. BladderGATE: Atezolizumab + intravesical BCG (bacillus Calmette-Guerin) upfront combination in patients with high risk non-muscle invasive bladder cancer (NMIBC)—Phase I-II ONCOSUR study.

Author

Castellano, Daniel, de Velasco, Guillermo, Esteban Villarrubia, Jorge, Dueñas, Marta, Paramio, Jesus, Garcia Martinez, Victor, Gomez, Carmen, Rodríguez-Izquierdo, Marta, Hernandez, Mario, Martin, Maria Paz, Álvarez, Pablo, Rodríguez Antolín, Alfredo, Suarez, Cristian, Morales, Lucía, Rubio, Carolina, Ponce Aix, Santiago, and Guerrero-Ramos, Félix

Published
2024
Full Text
View/download PDF

11. Dynamic profiling in patients with metastatic clear cell renal cell carcinoma (mRCC) undergoing first-line treatment with cabozantinib: A sub-exploratory analysis from CABOPRE trial.

Author

Álvarez, Pablo, Dueñas, Marta, Alonso Gordoa, Teresa, Rodriguez-Moreno, Juan Francisco, Carretero-González, Alberto, Ruiz-Granados, Álvaro, Martin Soberón, Maria Cruz, Sotelo, Marta, Esteban Villarrubia, Jorge, Paramio, Jesus, Castellano, Daniel, and de Velasco, Guillermo

Published
2024
Full Text
View/download PDF

13. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma

Author

San-Román-Gil, María, primary, Torres-Jiménez, Javier, additional, Pozas, Javier, additional, Esteban-Villarrubia, Jorge, additional, Albarrán-Fernández, Víctor, additional, Álvarez-Ballesteros, Pablo, additional, Chamorro-Pérez, Jesús, additional, Rosero-Rodríguez, Diana, additional, Orejana-Martín, Inmaculada, additional, Martínez-Delfrade, Íñigo, additional, Reguera-Puertas, Pablo, additional, Fuentes-Mateos, Raquel, additional, and Ferreiro-Monteagudo, Reyes, additional

Published
2023
Full Text
View/download PDF

18. Compresión medular por metástasis de melanoma

Author

Esteban Villarrubia, Jorge, primary, Torres Jiménez, Javier, additional, Álvarez Ballesteros, Pablo, additional, Orejana Martín, Inmaculada, additional, Sanz Gómez, Lucía, additional, Soto Castillo, Juan José, additional, Vida Navas, Elena, additional, San Román Gil, María Victoria, additional, Pozas Pérez, Javier, additional, and Soria Rivas, Ainara, additional

Published
2021
Full Text
View/download PDF

19. Novel Tyrosine Kinase Targets in Urothelial Carcinoma

Author

Torres-Jiménez, Javier, primary, Albarrán-Fernández, Víctor, additional, Pozas, Javier, additional, Román-Gil, María San, additional, Esteban-Villarrubia, Jorge, additional, Carrato, Alfredo, additional, Rosero, Adriana, additional, Grande, Enrique, additional, Alonso-Gordoa, Teresa, additional, and Molina-Cerrillo, Javier, additional

Published
2021
Full Text
View/download PDF

20. Tyrosine Kinase Receptors in Oncology

Author

Esteban-Villarrubia, Jorge, primary, Soto-Castillo, Juan José, additional, Pozas, Javier, additional, San Román-Gil, María, additional, Orejana-Martín, Inmaculada, additional, Torres-Jiménez, Javier, additional, Carrato, Alfredo, additional, Alonso-Gordoa, Teresa, additional, and Molina-Cerrillo, Javier, additional

Published
2020
Full Text
View/download PDF

21. 651 Neurological adverse events associated with immune checkpoint inhibitors: Our experience in a tertiary care center

Author

Alvarez-Ballesteros, Pablo, primary, Buisan-Catevilla, Javier, additional, Beltrán-Corbellini, Alvaro, additional, Corral-Corral, Iñigo, additional, Pozas-Perez, Javier, additional, Albarran-Fernandez, Victor, additional, Sanz-Gomez, Lucia, additional, Esteban-Villarrubia, Jorge, additional, Torres-Jimenez, Javier, additional, Chamorro-Perez, Jesús, additional, Rosero-Rodriguez, Diana, additional, Román-Gil, María San, additional, and Soria-Rivas, Ainara, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results